2004
DOI: 10.1007/s00228-003-0712-1
|View full text |Cite
|
Sign up to set email alerts
|

Methadone and edema: a case-report and literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2006
2006
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 4 publications
0
6
0
Order By: Relevance
“…Calcineurin inhibitors: 36 ciclosporin, tacrolimus Increased capillary permeability (as these drugs are responsible for capillary leak syndrome) mTOR inhibitors: 53 everolimus, sirolimus -lymphedema through antilymphangiogenic effects of VEGFR-3/VEGFC pathway inhibition 53 -increased capillary permeability 121 Pump proton inhibitors 122,123 lansoprazole, omeprazole, pantoprazole, rabeprazole Unknown Opioids Analgesics: [124][125][126] fentanyl, hydromorphone, morphine, oxycodone, tramadol -increased capillary permeability through nonspecific histamine releasing effects 124,127 -water retention through AVP release 125,127 Replacement therapy: methadone 127,128 Hypoglycemic sulfonamides: 129,130 Unknown thymoglobulin 36 Increased capillary permeability (as responsible for capillary leak syndrome)…”
Section: Immunosuppressantsmentioning
confidence: 99%
“…Calcineurin inhibitors: 36 ciclosporin, tacrolimus Increased capillary permeability (as these drugs are responsible for capillary leak syndrome) mTOR inhibitors: 53 everolimus, sirolimus -lymphedema through antilymphangiogenic effects of VEGFR-3/VEGFC pathway inhibition 53 -increased capillary permeability 121 Pump proton inhibitors 122,123 lansoprazole, omeprazole, pantoprazole, rabeprazole Unknown Opioids Analgesics: [124][125][126] fentanyl, hydromorphone, morphine, oxycodone, tramadol -increased capillary permeability through nonspecific histamine releasing effects 124,127 -water retention through AVP release 125,127 Replacement therapy: methadone 127,128 Hypoglycemic sulfonamides: 129,130 Unknown thymoglobulin 36 Increased capillary permeability (as responsible for capillary leak syndrome)…”
Section: Immunosuppressantsmentioning
confidence: 99%
“…The rash is often pruritic and purpuric or exanthematous in character and appears on the trunk, hands, feet and lower limbs for a period of 7 days. Some patients undergo a desquamative phase following this, which can last up to 4 weeks . While it still has to be determined whether this is due to hypersensitivity or contamination of methadone, it is important for all physicians to be aware of the association of rash with methadone.…”
Section: Discussionmentioning
confidence: 99%
“…1 There have been five publications describing a potential link with methadone in non-palliative care setting and peripheral oedema. [2][3][4][5][6] The earliest being Longwell 2 who describes three patients prescribed methadone for treatment of opioid addiction. All develop peripheral oedema within three to six months of commencing methadone, and in all cases, the oedema improves with subsequent reduction or stopping of methadone maintenance treatment.…”
Section: Discussionmentioning
confidence: 99%
“…There have been five published cases of the development of peripheral oedema following methadone, where most of these relate to methadone maintenance therapy. [2][3][4][5][6] This is the first report on the development of significant peripheral oedema following methadone treatment for neuropathic pain in the palliative care setting. The oedema subsequently resolved following cessation of methadone.…”
Section: Introductionmentioning
confidence: 95%